ItchBio’s lead asset, IB-242, is a topical therapeutic entering a P II trial for the treatment of pruritus in Eczema/Atopic Dermatitis and Psoriasis.
Employees
1-10Org chart
Collapse
No reports!
Teams
This company has no teams yet
Offices
This company has no offices yet
